Sanofi (NASDAQ:SNY) to Post FY2025 Earnings of $4.69 Per Share, Zacks Research Forecasts

Sanofi (NASDAQ:SNY) – Zacks Research decreased their FY2025 earnings per share (EPS) estimates for Sanofi in a research note issued to investors on Tuesday, October 15th. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $4.69 for the year, down from their prior forecast of $4.70. The consensus estimate for Sanofi’s current full-year earnings is $4.25 per share. Zacks Research also issued estimates for Sanofi’s Q1 2026 earnings at $1.33 EPS and FY2026 earnings at $5.08 EPS.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.95 EPS.

Several other research analysts also recently commented on the stock. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Argus boosted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Down 0.2 %

Shares of NASDAQ:SNY opened at $54.44 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a fifty day moving average of $56.00 and a 200 day moving average of $51.46. Sanofi has a 52-week low of $42.63 and a 52-week high of $58.97. The firm has a market capitalization of $137.88 billion, a PE ratio of 27.36, a price-to-earnings-growth ratio of 1.56 and a beta of 0.60.

Institutional Trading of Sanofi

Several hedge funds have recently bought and sold shares of the stock. EP Wealth Advisors LLC grew its holdings in Sanofi by 5.3% during the 4th quarter. EP Wealth Advisors LLC now owns 5,035 shares of the company’s stock valued at $250,000 after buying an additional 255 shares in the last quarter. HighPoint Advisor Group LLC bought a new position in shares of Sanofi during the 4th quarter valued at approximately $338,000. NBC Securities Inc. raised its holdings in Sanofi by 5.8% during the 1st quarter. NBC Securities Inc. now owns 21,619 shares of the company’s stock valued at $1,151,000 after buying an additional 1,189 shares during the period. GAMMA Investing LLC lifted its position in Sanofi by 30.5% in the first quarter. GAMMA Investing LLC now owns 2,119 shares of the company’s stock worth $103,000 after buying an additional 495 shares during the last quarter. Finally, Alaska Permanent Fund Corp purchased a new stake in shares of Sanofi in the first quarter valued at $237,000. Institutional investors own 10.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.